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Background: Subarachnoid hemorrhage (SAH) frequently results in several complications, including cerebral
vasospasm, associated with high mortality. Although cerebral vasospasm is a major cause of brain damages after
SAH, other factors such as inflammatory responses and oxidative stress also contribute to high mortality after SAH.
Trehalose is a non-reducing disaccharide in which two glucose units are linked by α,α-1,1-glycosidic bond, and has
been shown to induce tolerance to a variety of stressors in numerous organisms. In the present study, we
investigated the effect of trehalose on cerebral vasospasm, inflammatory responses, and oxidative stress induced by
blood in vitro and in vivo.
Methods: Enzyme immunoassay for eicosanoids, pro-inflammatory cytokines, and endothelin-1, and western
blotting analysis for cyclooxygenase-2, inducible nitric oxide synthase, and inhibitor of NF-κB were examined in
macrophage-like cells treated with hemolysate. After treatment with hemolysate and hydrogen peroxide, the levels
of lipid peroxide and amounts of arachidonic acid release were also analyzed. Three hours after the onset of
experimental SAH, 18 Japanese White rabbits received an injection of saline, trehalose, or maltose into the cisterna
magna. Angiographic and histological analyses of the basilar arteries were performed. In a separate study, the
femoral arteries from 60 rats were exposed to fresh autologous blood. At 1, 3, 5, 7, 10, and 20 days after treatment,
cryosections prepared from the femoral arteries were histologically analyzed.
Results: When cells were treated with hemolysate, trehalose inhibited the production of several inflammatory
mediators and degradation of the inhibitor of NF-κB and also suppressed the lipid peroxidation, the reactive oxygen
species-induced arachidonic acid release in vitro. In the rabbit model, trehalose produced an inhibitory effect on
vasospasm after the onset of experimental SAH, while maltose had only a moderate effect. When the rat femoral
arteries exposed to blood were investigated for 20 days, histological analysis revealed that trehalose suppressed
vasospasm, inflammatory response, and lipid peroxidation.
Conclusions: These data suggest that trehalose has suppressive effects on several pathological events after SAH,
including vasospasm, inflammatory responses, and lipid peroxidation. Trehalose may be a new therapeutic approach
for treatment of complications after SAH.
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Aneurysmal subarachnoid hemorrhage (SAH) is a serious
condition which often leads to high mortality and morbid-
ity [1]. Ischemic injury due to cerebral vasospasm is a
major cause of brain damage after SAH. However, cerebral
vasospasm is only considered one of the underlying causes
of SAH, and does not represent all of the associated clin-
ical manifestations. A recent study also demonstrated that
recovery of vasoconstriction by an endothelin antagonist
did not necessarily contribute to improved clinical out-
come [2], and additional mechanisms of secondary injury
besides vasospasm have been suggested [3].
SAH occurs after the rupture of an aneurysm on the
cerebral artery wall. Erythrocyte cytosol is released into
the subarachnoid space through hemolysis of erythro-
cytes. Oxyhemoglobin or a related high molecular weight
compound in erythrocyte cytosol can elicit a wide range
of stress responses, including activation of inflammatory
responses and production of inflammatory cytokines [4].
These actions are partially regulated by the NF-κB sig-
naling pathway. The NF-κB signaling pathway is essential
for host defense and inflammatory responses to extracel-
lular stimuli, but also has been associated with produc-
tion of inflammatory mediators after SAH [5]. It is also
known that the production of a class of arachidonic
acid-derived eicosanoids is enhanced in patients with
SAH [6]. In addition, oxidative stress, including lipid per-
oxidation, can occur following SAH due to excessive free
radicals generated by oxyhemoglobin and enzymatic
reactions, and plays important roles in the pathogenesis
of acute brain injury, development of vasospasm, and
breakdown of the blood brain barrier [7]. In support,
overexpression of antioxidant enzyme has been shown to
attenuate early brain injury after SAH [8].
A number of human and animal studies have been per-
formed on irrigation of the subarachnoid space for the
removal of blood clots, percutaneous transluminal angio-
plasty, anti-inflammatory agents including nonsteroidal
anti-inflammatory drugs and glucocorticoids, and antioxi-
dants including radical scavengers and lipid peroxidation
inhibitors [4,9,10]. However, there are still no definitive
treatments for complications including vasospasm after
SAH. As the underlying causes of the complications fol-
lowing SAH are multifactorial, effective treatment will
likely require a combination of approaches including clear-
ance of blood and the use of anti-oxidant reagents and
anti-inflammatory reagents, or a reagent with pleiotropic
effects.
Trehalose is a non-reducing disaccharide in which two
glucose units are linked by an α, α-1, 1-glycosidic bond.
Trehalose has multiple functions that distinguish it from
other common disaccharides, including a protective action
against stressors such as desiccation, reactive oxygen species
(ROS), and cold [11,12]. In addition, recent reports showedthat trehalose could prevent inflammatory responses
induced by endotoxic shock in vivo and in vitro [13,14]. As
such, trehalose is considered a potentially powerful thera-
peutic agent for various diseases, involving oxidative stress,
desiccating conditions, and chronic inflammation. Trehal-
ose is also considered to have a high safety profile as a tre-
halose-containing organ preservation solution is used in
clinical lung transplantation [15]. Furthermore, clinical
application of trehalose has been attempted for the cryo-
preservation of platelets, dry eye syndrome, and oral dry-
ness caused by dental treatment [16-18].
In the present study, we examined whether trehalose
could suppress oxidative stress, inflammatory responses,
and cerebral vasospasm after SAH.
Methods
Materials, animals and cell culture
Trehalose and maltose were purchased from Wako
(Osaka, Japan). The percentage of trehalose in solution
using the in vitro and in vivo experiments was selected
based on our preliminary data (data not shown).
Lipopolysaccharide (LPS) (from Escherichia coli O111:
B4) was from Sigma (St. Louis, MO, USA), and anisomy-
cin (from Streptomyces griseolus) was from Calbiochem
(San Diego, CA, USA).
Male Japanese White rabbits, male Wistar rats, and
male Sprague–Dawley (SD) rats were purchased from
Japan SLC (Hamamatsu, Japan). The design of the ani-
mal study was approved by the Animal Care Committee
of the Graduate School of Agricultural and Life Sciences,
The University of Tokyo.
We investigated the effect of trehalose on blood-
induced inflammatory responses in macrophage cells
and human umbilical vein endothelial cells (HUVECs).
These cells play important roles in inflammation after
SAH [19-22]. The hemolysate (see below) was used for
in vitro studies on blood-induced inflammation. The
murine macrophage cell line RAW 264.7 was obtained
from the RIKEN Cell Bank (Ibaraki, Japan). RAW 264.7
cells were cultured in Dulbecco’s Modified Eagle’s
Medium (DMEM) (Sigma) supplemented with 10% (v/v)
fetal bovine serum (FBS) (Gibco, Carlsbad, CA, USA)
and 1% (v/v) penicillin and streptomycin (Sigma).
HUVECs were obtained from Lonza (Basel, Switzerland).
HUVECs were grown in endothelial basal medium sup-
plemented with growth factors and FBS (EBM-2; Lonza).
Preparation of hemolysate
Hemolysates from Wistar rats (weighing approximately
250 g) were prepared according to a previously described
method [23], with slight modifications. The erythrocyte
fraction was washed three times with saline, and then
erythrocytes were divided into three parts and suspended
in either saline, 10% (w/v) trehalose (final concentration,
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and then gently sonicated for 30 s. After centrifugation,
the supernatants were collected as erythrocyte hemoly-
sates and stored at −80°C until use. Two absorbance
peaks at 540 and 576 nm were spectrophotometrically
measured in hemolysate samples, confirming the pres-
ence of oxyhemoglobin.
Enzyme immunoassay for eicosanoids, pro-inflammatory
cytokines, and endothelin-1
RAW 264.7 cells or HUVECs were incubated with or with-
out 10% hemolysate in the medium mixed with an equal
part of saline, 10% trehalose, or 10% maltose for 8 h or
18 h, and then washed three times with fresh medium.
After incubation for 1 h, the culture media were collected
and centrifuged at 15,000 rpm for 10 min. The superna-
tants were collected for tests. The supernatant concentra-
tions of prostaglandin E2 (PGE2), cysteinyl leukotriene,
human endothelin-1, tumor necrosis factor-α (TNF-α),
interleukin-6 (IL-6), interleukin-1α (IL-1α), and interleu-
kin-1β (IL-1β) were measured using enzyme immunoassay
(EIA) kits (the first two with kits from Cayman, Ann Arbor,
MI, USA; the remainder from R&D Systems, Minneapolis,
MN, USA) according to the manufacturer’s instructions.
Arachidonic acid release assay
RAW 264.7 cells were pre-incubated for 24 h in basal
medium containing 1 μCi [3H]-arachidonic acid/ml (Per-
kinElmer Life Sciences, Boston, MA, USA). The cells
were washed three times with Tyrode solution containing
10 mM HEPES-NaOH (pH 7.4) and 0.1% fatty acid-free
bovine serum albumin (Sigma) (wash buffer) and incu-
bated at 37°C for 3 h in wash buffer with 10% hemoly-
sates, 1.5 mM H2O2, or the corresponding vehicle. At
the end of the 3 h incubation period, the incubation
medium was removed and centrifuged at 10,000 rpm.
The supernatants were collected for tests. To determine
the radioactivity of released arachidonic acid, aliquots of
the supernatants were placed in scintillation vials con-
taining scintillation fluid, and radioactivity was measured
using a liquid scintillation counter LS6500 (Beckman
Coulter, Fullerton, CA, USA). To determine the radio-
activity of incorporated arachidonic acid, the cells that
remained attached to the plates were lysed using 2% NP-
40 substitute solution, and the cell lysate was utilized for
scintillation counting. The quantity of phospholipase A2
(PLA2) activity was shown as the total radioactivity
released per unit of incorporated radioactivity.
Western blotting analysis for cyclooxygenase-2, inducible
nitric oxide synthase, and IκB-α
RAW 264.7 cells were incubated with or without 10%
hemolysate, 20 ng/ml LPS, or 10 μM anisomycin in
medium mixed with an equal part of saline or 10%trehalose for 8 h or at the time points indicated in figure
legends. After washing with ice-cold PBS, cells were col-
lected and lysed using TNE buffer (10 mM Tris–HCl pH
7.8, 150 mM NaCl, 1 mM EDTA, and 1% NP-40) con-
taining 100 μg/ml aprotinin, 2 mM Na3VO4, 10 mM
NaF, and protease inhibitor cocktail (Roche, Basel, Switz-
erland). Immunoblotting with the specific antibodies
against COX-2 (Abcam, Cambridge, MA, USA), indu-
cible nitric oxygen synthase (iNOS) (Abcam), β-actin
(Sigma), inhibitor of NF-κB (IκB)-α (Cell Signaling Tech-
nology, Beverly, MA, USA), or the phosphorylated form
of IκB-α (Cell Signaling Technology) was performed
using SDS-solubilized cellular proteins. Protein images
were visualized by ImageQuant LAS-4000mini (Fujifilm,
Tokyo, Japan) and quantified by Multi Gauge (Fujifilm).
Measurement of lipid peroxide
RAW 264.7 cells were incubated with or without 10%
hemolysate treatment in the medium mixed with an
equal part of saline, 10% trehalose, or 10% maltose for
3 h. Collected cells were washed twice with PBS that
was deoxidized by N2 aeration. The level of lipid per-
oxide (LPO) in the cells was measured using an LPO
assay kit (Cayman) according to the manufacturer’s
instructions.
Angiographic and histological examinations in the rabbit
single-hemorrhage model
The rabbit single-hemorrhage model was used as previ-
ously reported [24], with some modifications. Eighteen
rabbits (weighing 2.8 kg to 3.4 kg) were anesthetized
with inhalation of isoflurane. Fresh autologous arterial
blood was drawn from the ear artery. After 1.0 mL of
cerebrospinal fluid was removed, 1.0 mL of blood was
immediately injected into the cisterna magna with the
animal in a tilted, head-down, prone position. The ani-
mal was maintained in the same position for 60 min to
allow the injected blood to coagulate around the basilar
artery. Three hours after the blood injection, the ani-
mal received an injection of 1.0 mL of saline, 30% tre-
halose, or 30% maltose into the cisterna magna in the
Saline, Trehalose, or Maltose groups, respectively. Prior
to and 48 h after the induction of experimental SAH, a
4 F angiographic catheter was inserted into the left ver-
tebral artery via the left femoral artery under fluoros-
copy, and angiography of the basilar artery was
performed by manual injection of 0.5 mL iohexol
(350 mg of iodine/mL; Daiichi-Sankyo, Tokyo, Japan).
After the angiography, mannitol (0.5 mg/kg/h; Yoshindo,
Toyama, Japan) was administered intravenously to prevent
increased intracranial pressure.
Angiographic images of the basilar artery were adjusted
with TOSPAC (Total System Performance Assessment
Code; Toshiba, Tokyo, Japan). The diameter of the basilar
Figure 1 Effects of trehalose on inflammatory responses in cultured cells. As indicated in the graphs, culture media, hemolysate, or both
contained saline (Sal), 5% trehalose (Tre), or 5% maltose (Mal). (A, B) Effect of trehalose on the induction of eicosanoids in hemolysate-treated cells.
RAW 264.7 cells were treated with or without 10% hemolysates for 8 h. Prostaglandin E2 (PGE2) (A) and cysteinyl leukotriene (B) levels were measured
by enzyme immunoassay (EIA). n = 4 (A) and n=5 (B) in each group, respectively. (C) Effect of trehalose on production of cyclooxygenase-2 (COX-2) in
hemolysate-treated cells. RAW 264.7 cells were treated with 10% hemolysates, vehicle, or 20 ng/ml LPS (used as a positive control) for 8 h. The
amounts of COX-2 and β-actin (used as an internal control) were analyzed by western blotting. The graph shows the band intensities of COX-2,
adjusted to the corresponding β-actin bands and calculated as intensity ratio relative to that of the saline control. n = 5 in each group. (D) Effect of
trehalose on the release of arachidonic acid in hemolysate-treated cells. RAW 264.7 cells were prelabeled with [3H]-arachidonic acid and then treated
with or without 10% hemolysate for 3 h. The radioactivity was measured to quantify arachidonic acid release. n =7 in each group. (E) Effect of
trehalose on the induction of endothelin-1 in hemolysate-treated cells. Human umbilical vein endothelial cells (HUVECs) were treated with or without
10% hemolysates for 18 h. Endothelin-1 levels were measured by EIA. n =5 in each group. (F, G) Effect of trehalose on the induction of pro-
inflammatory cytokines in hemolysate-treated cells. RAW 264.7 cells were treated with or without 10% hemolysates for 8 h. Tumor necrosis factor-α
(TNF-α) (F) and interleukin-1β (IL-1β) (G) levels were measured by EIA. n =3 (F) and n=4 (G) in each group, respectively. (H) Effect of trehalose on the
production of inducible nitric oxygen species (iNOS) in hemolysate-treated cells. RAW 264.7 cells were treated with vehicle, 10% hemolysates, or
20 ng/ml LPS for 8 h. Amounts of iNOS and β-actin were analyzed by western blotting. The graph shows the band intensities of iNOS, adjusted to
the corresponding β-actin bands and calculated as intensity ratio relative to that of the saline control. n = 7 in each group. Whole experiments were
repeated more than three times. All data are shown as means ± SD. *P< 0.05 (Kruskal-Wallis test).
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locations: distal, middle, and proximal. The length be-
tween the distal and proximal locations was set to 100
pixels on the computer monitor, and the middle loca-
tion was set as 50 pixels from the distal and proximal
locations. The real length per pixel was evaluated by
measuring a 2 mm lead ball recorded at the same time
as the basilar artery. These measurements were per-
formed using a blinded method.
After perfusion fixation with 200 ml of PBS and 450 ml
of 4% paraformaldehyde mixed with 50 ml of 25% glutaral-
dehyde, the basilar arteries were sampled. Paraffin sections
(3 μm thick) of the basilar artery were prepared and then
stained with hematoxylin and eosin (H&E). The cross-sec-
tional area of the vessel lumen was determined by measur-
ing the circumference of the vessel lumen and calculating
the area as a generalized circle. These measurements were
also performed using a blinded method.Rat femoral artery vasospasm model and immunostaining
for cyclooxygenase-2, inducible nitric oxide synthase, and
7-ketocholesterol
We used the rat model for vasospasm established by
Okada et al. [25], with modifications. After anesthesia with
intraperitoneal injection of pentobarbital (50 mg/kg), both
the left and right femoral arteries and veins in 60 rats
(weighing 300 to 350 g) were covered with a vinyl chloride
catheter (10 mm in length). Fresh autologous blood was
drawn from the femoral vein and mixed 3:1 with saline or
15% trehalose solution; the final concentration of trehalose
was 3.75%. The mixture was immediately injected into the
strip of the left artery to fill it up. Saline alone was injected
into the strip of the right artery as a control. At 1, 3, 5, 7,
10, and 20 days after treatment, cryosections (3 μm thick)
of both femoral arteries were prepared and then stained
with H&E. The cross-sectional area of the vessel lumen
was determined by measuring the circumference of the
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cle. The wall media thickness was averaged among four
distant sites. These measurements were performed using a
blinded method. For each parameter, the ratio of the value
in the left artery (tested artery) to that in the right artery
(control artery) was calculated.
The cryosections were incubated overnight at 4°C with
or without primary antibodies against cyclooxygenase-2
(COX-2) (1:500; Abcam), inducible nitric oxide synthase
(iNOS) (1:500; Abcam), and 7-ketocholesterol (7-KC)
(1:500; NOF, Tsukuba, Japan). Antibody localization was
detected with HRP-conjugated secondary antibody (Pro-
mega, Madison, WI, USA) and diaminobenzidine (DAKO,
Carpinteria, CA, USA). The sections were counterstained
with methylgreen.
Statistical analyses
Data are expressed as means ± SD or median and range,
and were analyzed for significance by Kruskal-Wallis test
with Bonferroni’s correction or, when indicated, by
Mann-Whitney’s U test. Values of p< 0.05 were consid-
ered statistically significant.
Results
Trehalose suppressed blood-induced inflammatory
responses in vitro
To confirm the effect of hemolysate on the arachidonic
acid cascade, murine macrophage-like cells (RAW 264.7)
were treated with 10% concentrations of hemolysate for
various time periods. This treatment induced a significant
time-dependent increase in the production of the eicosa-
noid PGE2 (Additional file 1: Figure S1A). Similar effects
were observed in the production of cysteinyl leukotrienes
(data not shown). To determine whether trehalose attenu-
ated the production of PGE2, trehalose was mixed with
hemolysate (pre-treatment), with the culture medium, or
with both. Compared with the saline control, the incre-
ment in PGE2 production induced by hemolysate was
significantly reduced by pre-treatment of the hemolysate
with trehalose or by the presence of trehalose in the cul-
ture medium (Additional file 1: Figure S1B). While pre-
treatment was more effective than for culture medium
treatment, the strongest effect was observed when the two
were combined (Additional file 1: Figure S1B). By contrast,
maltose, a structural isomer of trehalose with an α, α-1,4
glycosidic bond, had no effect on PGE2 production
(Figure 1A). Similar results were obtained using HUVECs
(Additional file 1: Figure S1C). Trehalose also suppressed
the production of cysteinyl leukotrienes and prostaglandin
D2, suggesting that trehalose treatment attenuates both
COX and 5-lipoxygenase (5-LO) pathways, which
metabolize arachidonic acid into prostaglandins and leuko-
trienes, respectively (Figure 1B and Additional file 1:
Figure S1D). Indeed, western blotting analysis revealedthat the production of COX-2 (an inducible isoform of
COX) elicited by hemolysate was significantly diminished
by trehalose treatment in vitro (Figure 1C).
Next we evaluated the effect of trehalose on the action of
cytosolic phospholipase A2s (cPLA2s), which act upstream
from COXs and 5-LO as rate-limiting enzymes in the ara-
chidonic acid cascade, in hemolysate-treated cells. Treat-
ment with hemolysate significantly increased the level of
[3H]-arachidonic acid release when saline or maltose was
used (Figure 1D). Trehalose treatment suppressed hemoly-
sate-induced [3H]-arachidonic acid release (Figure 1D). To
examine whether trehalose directly suppressed the enzyme
activity of cPLA2, the phospholipid-cleaving activity of
cPLA2s was evaluated in the presence of trehalose. The
cPLA2s effectively cleaved the phospholipids in the pres-
ence or absence of trehalose (Additional file 1: Figure S1E),
indicating that the reduction in lipid mediators by trehalose
was not due to direct suppression of the enzyme activity of
cPLA2s. The production of endothelin-1, which is a potent
vasoconstrictor and which was reported to be increased by
treatment with hemolysate in cultured endothelial cells
[26], was also suppressed by trehalose in HUVECs
(Figure 1E).
Induction of various pro-inflammatory cytokines has
been observed in both hemolysate-treated cells and ex-
perimental SAH models [5,23,27]. To investigate the
effect of trehalose on cytokine expression, the levels of
TNF-α, IL-6, IL-1α, and IL-1β were measured in hemoly-
sate-treated cultured cells. Trehalose significantly sup-
pressed the hemolysate-induced productions of these
cytokines (Figure 1F and G, and Additional file 1: Figure
S1F and G). iNOS expression also plays an important
role in the pathogenesis of cerebral injury after experi-
mental SAH [20]. Thus, we examined the effect of tre-
halose on iNOS production induced by hemolysate
treatment in cultured cells. Western blotting analysis
showed that iNOS production was increased by hemoly-
sate, but significantly reduced in trehalose-treated cells
(Figure 1H).
Overall, these data suggest that trehalose inhibits the
inflammatory responses induced by hemolysate in vitro.
Trehalose suppressed activation of NF-κB induced by
hemolysate in vitro
NF-кB is activated in the arterial wall after experimental
SAH, which may lead to induction of an inflammatory re-
sponse including production of several cytokines [5]. We
examined whether trehalose suppressed the activation of
NF-кB in hemolysate-treated macrophage cells in vitro.
NF-кB is activated by the phosphorylation and resultant
degradation of IκB. Western blotting analysis showed that
both the phosphorylation and degradation of IкB-α were
induced by hemolysate treatment (Figure 2A and B). Both
of these effects were clearly suppressed by trehalose
Figure 2 Effects of trehalose on the NF-кB pathway activated by hemolysate treatment. (A) Effect of trehalose on IкB-α phosphorylation
and degradation in hemolysate-treated cells. RAW 264.7 cells were treated with 10% hemolysates or vehicle for 80 min. Cells were collected at the
indicated time points, and then SDS samples were prepared. Amounts of phosphorylated IкB-α (P-IкB-α), total IкB-α (IкB-α), and β-actin were
analyzed by western blotting. (B) The graph shows changes in the band intensities of total IкB-α, adjusted to the corresponding β-actin bands
and calculated as intensity ratio relative to that of 0 min time-point, for 0, 20, 40, and 80 min. *P< 0.05 as compared to saline (Mann–Whitney‘s U
test). n = 4 in each group. Whole experiments were repeated more than three times. All data are means ± SD.
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B). These data suggest that trehalose suppresses the in-
flammatory responses induced by hemolysate via inhib-
ition of the canonical NF-кB pathways.
Trehalose protected against hemolysate- and ROS-induced
oxidative stress in vitro
Oxidative stress, including lipid peroxidation, has also
been shown to contribute to cell injury and progression
of early brain injury and cerebral vasospasm after SAH
[8,28]. Oxyhemoglobin released from the lysis of red
blood cells is considered to play a major role in oxida-
tive cell damage via lipid peroxidation in and around the
cerebral artery [4,28]. Furthermore, superoxide anion
radicals and hydroxyl radicals, which are generated by
and released from oxyhemoglobin, are involved in lipid
peroxidation [4]. Thus, we examined whether trehalose
directly suppressed the generation of LPO. Colorimetric
analysis confirmed that lipid peroxidation was stimu-
lated by treatment with hemolysate in cultured cells
(Figure 3A). Hemolysate-induced lipid peroxidation was
significantly suppressed by trehalose, but not by maltose
(Figure 3A). Next, to examine the effect of trehalose on
the oxidative stress-induced arachidonic acid release, we
performed an arachidonic acid release assay primed by
H2O2 in cultured cells. H2O2 was previously reported to
induce arachidonic acid release via the lipid peroxida-
tion [29,30]. In our assay, trehalose significantly sup-
pressed H2O2-primed arachidonic acid release, while
there was no effect of maltose (Figure 3B). These data
suggest that trehalose directly reduces oxidative stress,
including lipid peroxidation, induced by hemolysate and
ROS.
To elucidate the mechanism by which trehalose sup-
pressed oxidative stress, we investigated the effect of tre-
halose on the scavenging of free radicals using electron
spin resonance spectroscopy with the spin-trap reagent 5-
(2,2-dimethyl-1,3-propoxy cyclophosphoryl)-5-methyl-1-
pyrroline N-oxide (CYPMPO) [31]. There was no effect of
trehalose on the generation of super oxide anions using a
hypoxanthine/xanthine oxidase system, whereas trehalose
reduced the generation of hydroxyl radicals using a Fenton
reaction, suggesting that trehalose scavenged hydroxyl
radicals (Additional file 1: Figure S2). However, the scaven-
ging effect of hydroxyl radicals was also observed with
maltose (Additional file 1: Figure S2). Thus, these data sug-
gest that the suppression mechanism of blood- and ROS-
induced lipid peroxidation by trehalose is not primarily the
result of the scavenging of free radicals.
Trehalose suppressed cerebral vasospasm after the onset
of experimental SAH in the rabbit model
To test the effect of trehalose on cerebral vasospasm
after experimental SAH, we used the rabbit single-hemorrhage model. In preliminary experiments, blood
mixed with saline, 3.8% trehalose, or 7.5% trehalose was
administered into the cisterna magna of rabbits (co-
administration model). Angiography revealed that the
blood-induced vasospasm was weaker in the blood + tre-
halose group than in the saline group (Additional file 1:
Figure S3). Trehalose at a concentration of 3.8% was less
effective for the suppression of vasospasm than that of
7.5% (data not shown).
Next, to examine the effect of trehalose on cerebral vaso-
spasm in a near-clinical setting, saline or trehalose at a final
concentration of 7.5% was administered into the cisterna
magna in a single dose at 3 h after blood injection (post-
administration model). Blood in the cisterna magna was
considered to be clotted at 3 h after blood injection.
Similar to the case of co-administration of trehalose and
blood, the vasospasm was significantly abrogated by post-
administration of trehalose but not by post-administration
of saline (Figure 4A and B). Maltose had a moderate inhibi-
tory effect on vasospasm (Figure 4A and B). Histological
analysis revealed that the characteristic features of vaso-
spasm (reduction in the sectional area, thickening of the ar-
terial wall, increase in endothelial cells, and corrugated
internal elastic lamina) were observed in the basilar arteries
of the saline- or maltose-injected animals, whereas the
vasospasm was attenuated in the trehalose-injected animals
(Figure 4C). Quantification of the cross-section of the basi-
lar artery also revealed that post-injection of trehalose
significantly suppressed the cerebral vasospasm (Figure 4D).
Taken together, these data suggest that trehalose has a spe-
cific suppressive effect on the cerebral vasospasm caused
by experimental SAH, even when administered after the
onset of experimental SAH.
Trehalose treatment abrogated blood-induced vasospasm,
inflammatory responses, and lipid peroxidation in the
presence of blood in the rat femoral artery model
In our rabbit model studies, it was not clear whether trehal-
ose directly suppressed vasospasm or whether it facilitated
the recovery from vasospasm in arterial tissue exposed to
blood. To address this question, we performed the time-
course experiments using the rat femoral artery vasospasm
model, which is analogous to clinical and experimental
SAH in terms of the temporal evolution of vascular nar-
rowing and morphological changes [25]. Control arteries
exposed to saline for 7 days were similar in appearance to
normal arteries (Figure 5B). Time-course experiments
showed that the reduction in the sectional area and the
thickening of the arterial walls both peaked at 7 days after
treatment with a mixture of blood and saline (blood +
saline), while these changes were suppressed by trehalose
(final concentration of 3.75%) (Figure 5A). On day 7, the
characteristics of vasospasm were clearly observed in the
arteries treated with blood + saline (Figure 5B). By contrast,
Figure 3 Effects of trehalose on hemolysate-induced and ROS-induced oxidative stress in cultured cells. As indicated in the graphs, the
culture media, hemolysate, or both contained saline (Sal), 5% trehalose (Tre), or 5% maltose (Mal). (A) Measurement of lipid peroxide (LPO) using
colorimetric analysis. RAW 264.7 cells were treated with or without 10% hemolysates for 3 h. LPO levels were measured by a colorimetric assay
using ferrous iron molecules. n = 6 in each group. (B) Effect of trehalose on the release of arachidonic acid in H2O2-treated cells. RAW 264.7 cells
were prelabeled with [3H]-arachidonic acid overnight and then treated with or without 1.5 mM H2O2 for 3 h. The radioactivity of the collected
culture media was measured to quantify arachidonic acid release. (Kruskal-Wallis test). n = 4 in each group. All experiments were repeated more
than three times. All data are shown as means ± SD. *P< 0.05 (Kruskal-Wallis test).
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changes (Figure 5B). Trehalose was also effective at final





























































Figure 4 Effects of trehalose on cerebral vasospasm in experimental S
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Figure 5 Effects of trehalose on inflammatory responses, oxidative stress, and vasospasm in the presence of blood. (A) Changes in the
luminal cross-sectional area and thickness of the arterial media of femoral vessels exposed to saline or to blood containing either saline or
trehalose for 1, 3, 5, 7, 10, and 20 days. The ratios of the luminal cross-sectional area and the thickness of the arterial media of femoral vessels
exposed to blood containing either saline (Sal) or 3.75% trehalose (Tre) to those exposed to saline alone were calculated. **P< 0.01 and
***P< 0.005 * as compared with saline (Mann–Whitney‘s U test). n = 6 in each group. (B) Representative H&E-stained cryosections (3 μm thick) of
femoral arteries exposed to saline alone (Saline) or to blood containing either saline (Blood + Saline) or 3.75% trehalose (Blood + Trehalose) at
7 days. Scale bars, 200 μm. (C) Immunohistological analysis in the rat artery vasospasm model. The cryosections (3 μm thick) were immunostained
with or without antibodies (Ab) against COX-2, iNOS, or 7-ketocholesterol (KC) and then counterstained with methyl green. Scale bars, 20 μm. All
experiments were repeated more than three times. All data are shown as means ± SD.
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tivation of inflammatory responses and production of lipid
peroxide induced by blood. We performed immunohisto-
chemical analysis for the inflammatory markers COX-2
and iNOS in the rat models. In the blood + saline groups,
endothelial cells in the intimal layer were stained with the
COX-2 antibody, and endothelial cells in the intimal layer
and fibroblasts in the adventitial layer were stained with
the iNOS antibody (Figure 5C). By contrast, the immunos-
taining intensities for both COX-2 and iNOS were mark-
edly diminished in the blood + trehalose groups and the
negative control groups (Figure 5C). Immunohistochem-
ical analysis also detected 7-KC, a marker for lipid peroxi-
dation and a non-enzymatic oxidant of cholesterol [29], in
smooth muscle cells of medial layer in the blood + saline
group. By contrast, 7-KC production was not observed in
the blood + trehalose group (Figure 5C). These data sug-
gest that trehalose suppresses inflammatory responses and
lipid peroxidation as well as the induction of vasospasm
in vivo.
Discussion
In the present study, we demonstrate that (1) trehalose
suppressed hemolysate-induced inflammatory responses
including activation of the arachidonic acid cascade and
production of iNOS, pro-inflammatory cytokines, and
endothelin-1 in cultured cells; (2) trehalose suppressed acti-
vation of the NF-κB pathway in the hemolysate-treated cul-
tured cells; (3) trehalose protected cells from hemolysate-
and ROS-induced lipid peroxidation in the cultured cells;
(4) a single administration of trehalose after the onset of ex-
perimental SAH suppressed blood-induced vasospasm in
the rabbit single-hemorrhage model; and (5) trehalose sup-
pressed development of vasospasm, as well as inflammatory
responses and lipid peroxidation in the presence of blood
in the rat femoral artery model.
Putative mechanisms of suppression of vasospasm by
trehalose in subarachnoid space after the onset of
experimental SAH
Our rabbit model studies showed that a single administra-
tion of trehalose even after the onset of experimental SAH
suppressed cerebral vasospasm. In addition, we observed
that trehalose suppressed development of vasospasm even
in the presence of blood in the rat femoral artery model.
These results suggest that trehalose, by remaining in the
subarachnoid space, can suppress complications of SAH
even if the blood clots are remained. It is unclear how tre-
halose exerts this anti-vasospasm effect on arterial tissue.
Nevertheless, autoradioluminogram of the rabbits after
intraperitoneal administration of radiolabeled-trehalose
revealed that trehalose remained in intraperitoneal cavity
and was relatively localized on the organ surface (likely
through interaction with membrane) for several hours,while the trehalose was then transported to various other
organs within 24 h (S. Kuribayashi, Personal communica-
tion). Therefore, similarly in the intraperitoneal space, tre-
halose may remain in the subarachnoid space for several
hours and suppress cerebral vasospasm through its mem-
brane-protective effect.
Putative mechanisms of the anti-inflammatory effect of
trehalose after treatment with blood
A number of reports have suggested an association be-
tween inflammatory responses and complications such as
cerebral vasospasm after SAH [4,27,32]. We observed that
hemolysate induced the production of several inflamma-
tory mediators as well as the activation of NF-кB in vitro.
We also confirmed that COX-2 and iNOS were produced
in the rat femoral artery model, similar to the results with
experimental SAH models previously described [19,20].
Our in vivo and in vitro studies clearly showed trehalose
suppressed these inflammatory responses.
Production of the lipid mediators is mainly controlled
by cPLA2. However, trehalose did not directly inhibit the
enzyme activity of cPLA2, despite a decrease in produc-
tion of lipid mediators and arachidonic acid release
induced by hemolysate treatment in cultured cells. The
Ca2+-independent PLA2 (iPLA2, group VI PLA2) is
involved in arachidonic acid release induced by various
stimulations and nicotine-induced contraction in the
basilar artery via arachidonic acid metabolites [33,34].
Thus, iPLA2 may be involved in arachidonic acid release
and vasospasm induced by blood, and trehalose may sup-
press the enzyme activity of iPLA2.
Production of pro-inflammatory mediators is partially
regulated by the NF-кB pathway [35-37]. Our findings,
in combination with those previously reported, suggest
that trehalose suppresses the blood-induced inflamma-
tory responses by inhibiting the NF-кB pathway. In sup-
port of these data, previous studies have demonstrated
that trehalose prevented pro-inflammatory activation by
endotoxic shock both in vitro and in vivo, potentially
through several signaling pathways including the NF-кB
pathway [13,14]. Thus, trehalose may be useful as a novel
anti-inflammatory therapy.
We observed that pre-treatment of the hemolysate with
trehalose was more effective than the presence of trehalose
in culture medium for relieving blood-induced lipid medi-
ator production in vitro. Sphingosylphosphorylcholine was
recently identified as a pro-inflammatory factor after ex-
perimental SAH [38]. The anti-inflammatory effect of tre-
halose may be derived, at least in part, from inactivation of
such pro-inflammatory factor (s). We also consider that the
anti-inflammatory actions of trehalose are regulated by an
identified or unidentified trehalose receptor expressed on
the cell surface, and that this receptor attenuates activation
of the signal transduction cascade such as the arachidonic
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suggested that LPS-induced cytokine productions might be
inhibited by trehalose via the T1R3 trehalose receptor in
macrophage cells [39].
Putative mechanisms of the antioxidant effect of
trehalose after treatment with blood
The development of cerebral injury after SAH is trig-
gered by oxidative stress including lipid peroxidation of
the cell membrane [7]. Herein, we showed that trehalose
suppressed the generation of lipid peroxidation induced
by blood. Consistent with these data, trehalose was pre-
viously reported to suppress ROS-induced lipid peroxi-
dation in yeast cells [40]. Trehalose may suppress lipid
peroxidation by directly interacting with the membrane
and thereby suppressing radical oxidation of unsaturated
fatty acids [41]. Although trehalose appears to have an
effect similar to free radical scavengers, the mechanism
of action of trehalose clearly differs from that of free rad-
ical scavengers in that it protects the cell membrane.
The effect of maltose on vasospasm, inflammation, and
lipid peroxidation
While maltose had a moderate effect on vasospasm in vivo
unlike trehalose, it was not effective in reducing blood-
induced inflammation and lipid peroxidation. These
results are in accordance with a previous report showing
that maltose had no effect on an endotoxin-induced pro-
inflammatory phenotype [14]. It is likely that the anti-
inflammatory and antioxidant effects of trehalose are
derived from its unique structural properties, not observed
in maltose, that strongly interact with proteins and lipids
through hydrogen bonding [42]. Further studies are
required to determine the effect of trehalose on various
pro-inflammatory factors and oxidants.
Possible clinical use of trehalose after SAH
The most well established method for preventing the com-
plications of SAH includes cisternal irrigation therapy with
urokinase and intracisternal administration of tissue plas-
minogen activator. We found that injection of trehalose
into the subarachnoid space after the onset of experimental
SAH was able to inhibit vasospasm. Thus, in the clinical
setting, we suggest that cisternal irrigation fluid is the opti-
mal route of trehalose administration, and is anticipated to
have an additional or synergistic therapeutic effect on com-
plications of SAH when combined with existing therapeutic
modalities.
Study limitations
There are some limitations in this study. First, while we
showed suppressive effects of trehalose on inflammation,
oxidative stress, and vasospasm, we could not fully elucidate
the relationship between these pathological mechanismsand the effects of trehalose. Secondly, although we consider
that trehalose could be administered with cisternal irriga-
tion therapy in the clinical setting, we examined the effect
of trehalose on vasospasm via a bolus injection into the cis-
ternal space, not cisternal irrigation. Thirdly, we only exam-
ined the inflammatory response and oxidative stress in the
femoral arterial walls only. Finally, we did not evaluate any
cerebral function and morphology such as mortality, neuro-
logical function, cerebral blood flow, and neuronal cell
death in the rabbit model.
Conclusions
We demonstrated that periadventitial treatment with tre-
halose can produce pleiotropic actions including inhibition
of inflammatory responses, lipid peroxidation, and vaso-
spasm. The presence of these multiple effects is advanta-
geous compared with other drug candidates such as radical
scavengers or anti-inflammatory reagents that exert only a
single action. Trehalose has already been used as an organ
preservation solution in clinical transplantation, and has no
side effects. Thus, trehalose may be a potential therapeutic
option for patients with SAH, either as monotherapy or in
combination with other treatment modalities.
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